Quidel Corp. (QDEL) PT Raised to $27 at Barclays; Reiterates Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Quidel Reports First Quarter 2017 Financial Results
April 24, 2017 4:10 PM EDTSAN DIEGO, CA -- (Marketwired) -- 04/24/17 -- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2017.
First Quarter 2017 Highlights:
Total revenue was $73.7 million as compared to $50.3 million in the first quarter of 2016.Total influenza revenue increased 112% from the first quarter of 2016 to $40.8 million. Total Molecular revenues increased 48%... More